Landmark cardiovascular/renal outcome trials show GLP-1 receptor agonists lower the risk of major cardiovascular events and kidney failure — benefits now reported to extend to type 1 diabetes populations, broadening the therapeutic case for the class beyond weight loss and glycemic control.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.